Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Camp4 Therapeutics (CAMP) Gains from Investment Securities (2023 - 2025)

Camp4 Therapeutics' Gains from Investment Securities history spans 3 years, with the latest figure at $178000.0 for Q4 2025.

  • For Q4 2025, Gains from Investment Securities rose 85.42% year-over-year to $178000.0; the TTM value through Dec 2025 reached $111000.0, up 117.93%, while the annual FY2025 figure was $111000.0, 69.51% down from the prior year.
  • Gains from Investment Securities for Q4 2025 was $178000.0 at Camp4 Therapeutics, up from -$357000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $398212.0 in Q3 2024 and bottomed at -$893000.0 in Q4 2023.
  • The 3-year median for Gains from Investment Securities is $137000.0 (2024), against an average of -$13723.5.
  • The largest annual shift saw Gains from Investment Securities skyrocketed 110.75% in 2024 before it plummeted 189.65% in 2025.
  • A 3-year view of Gains from Investment Securities shows it stood at -$893000.0 in 2023, then skyrocketed by 110.75% to $96000.0 in 2024, then surged by 85.42% to $178000.0 in 2025.
  • Per Business Quant, the three most recent readings for CAMP's Gains from Investment Securities are $178000.0 (Q4 2025), -$357000.0 (Q3 2025), and $254000.0 (Q2 2025).